BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
06 mai 2020 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...